JP Morgan Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $25

Benzinga · 3d ago
JP Morgan analyst Chris Schott maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and raises the price target from $24 to $25.